Cargando…
Using biomarkers to adjust corticosteroid dose in patients with severe asthma
Use of biomarkers may help reduce inhaled corticosteroid burden in severe asthma if treatment advice is followed. T2 low asthma is less common than previously thought. https://bit.ly/3rG7SZ2
Autor principal: | Jones, Thomas L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8291938/ https://www.ncbi.nlm.nih.gov/pubmed/34295402 http://dx.doi.org/10.1183/20734735.0324-2020 |
Ejemplares similares
-
Therapeutic Inertia in Prescribing Biologics for Patients with Moderate-to-Severe Asthma: Workshop Summary
por: Sico, Isabelle P, et al.
Publicado: (2021) -
Novel therapies for severe asthma in children and adults
por: Delimpoura, Vasiliki, et al.
Publicado: (2018) -
Is there clinical value in performing capsaicin cough challenges in patients with severe asthma?
por: King, Jenny, et al.
Publicado: (2021) -
Withdrawal of inhaled corticosteroids in COPD patients: rationale and algorithms
por: Avdeev, Sergey, et al.
Publicado: (2019) -
Can vitamin D(3) supplementation reduce the time to severe asthma exacerbations in children with asthma?
por: Bokobza, Idan, et al.
Publicado: (2021)